INOTUZUMAB OZOGAMICIN FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN THE GLOBAL PHASE 3 RANDOMIZED CONTROLLED INO-VATE TRIAL: EFFICACY AND SAFETY BY PRIOR THERAPY

被引：0
|
作者：
DeAngelo, D. J. [1 ]
Jabbour, E. J. [2 ]
Stelljes, M. [3 ]
Liedtke, M. [4 ]
Stock, W. [5 ]
Goekbuget, N. [6 ]
Martinelli, G. [7 ]
O'Brien, S. [8 ]
Wang, K. [9 ]
Wang, T. [10 ]
Paccagnella, M. L. [10 ]
Sleight, B. [10 ]
Vandendries, E. [11 ]
Advani, A. S. [12 ]
Kantarjian, H. M. [2 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Klinikum mUNSTER, Munster, Germany
[4] Stanford Canc Ctr, Stanford, CA USA
[5] Univ Chicago Med, Chicago, IL USA
[6] Univ Hosp Frankfurt, Frankfurt, Germany
[7] Univ Bologna, Bologna, Italy
[8] Univ Calif Irvine, Orange, CA 92668 USA
[9] Pfizer Inc, Pearl River, NY USA
[10] Pfizer Inc, Groton, CT 06340 USA
[11] Pfizer Inc, Cambridge, MA USA
[12] Cleveland Clin Main Campus, Cleveland, OH USA
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S499
引用
收藏
页码：184 / 184
页数：1
相关论文
共 50 条
  • [21] Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study
    Kantarjian, Hagop M.
    DeAngelo, Daniel J.
    Stelljes, Matthias
    Liedtke, Michaela
    Stock, Wendy
    Goekbuget, Nicola
    O'Brien, Susan M.
    Jabbour, Elias
    Wang, Tao
    White, Jane Liang
    Sleight, Barbara
    Vandendries, Erik
    Advani, Anjali S.
    CANCER, 2019, 125 (14) : 2474 - 2487
  • [22] Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): Analysis from INO-VATE by bone marrow blast percentage (BMB%).
    Advani, Anjali S.
    DeAngelo, Daniel J.
    Marks, David I.
    Stelljes, Matthias
    Liedtke, Michaela
    Stock, Wendy
    Goekbuget, Nicola
    O'Brien, Susan Mary
    Jabbour, Elias
    Merchant, Akil Abid
    Wang, Tao
    Vandendries, Erik
    Neuhof, Alexander
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Patient-Reported Outcomes From a Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
    Kantarjian, Hagop M.
    Su, Yun
    Jabbour, Elias J.
    Bhattacharyya, Helen
    Yan, Eric
    Cappelleri, Joseph C.
    Marks, David I.
    CANCER, 2018, 124 (10) : 2151 - 2160
  • [24] Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study
    Kantarjian, Hagop M.
    DeAngelo, Daniel J.
    Advani, Anjali S.
    Stelljes, Matthias
    Kebriaei, Partow
    Cassaday, Ryan D.
    Merchant, Akil A.
    Fujishima, Naohito
    Uchida, Toshiki
    Calbacho, Maria
    Ejduk, Anna A.
    O'Brien, Susan M.
    Jabbour, Elias J.
    Zhang, Hui
    Sleight, Barbara J.
    Vandendries, Erik R.
    Marks, David I.
    LANCET HAEMATOLOGY, 2017, 4 (08): : E387 - E398
  • [25] PATIENT-REPORTED OUTCOMES FROM A GLOBAL PHASE 3 RANDOMIZED CONTROLLED TRIAL OF INOTUZUMAB OZOGAMICIN VERSUS STANDARD CARE FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
    Kantarjian, H. M.
    Su, Y.
    Bhattacharyya, H.
    Yan, E.
    Shapiro, M.
    Cappelleri, J. C.
    HAEMATOLOGICA, 2016, 101 : 202 - 202
  • [26] Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
    Kantarjian, Hagop M.
    Su, Yun
    Jabbour, Elias J.
    Bhattacharyya, Helen
    Yan, Eric
    Shapiro, Mark
    Cappelleri, Joseph C.
    Marks, David I.
    BLOOD, 2016, 128 (22)
  • [27] Exploration of Potential Relationships between CD22 and Selected Safety Outcomes in the Inotuzumab Ozogamicin Phase 3 INO-VATE Study
    Kebriaei, Partow
    DeAngelo, Daniel J.
    Advani, Anjali S.
    O'Brien, Susan M.
    Marks, David
    Kantarjian, Hagop M.
    Jabbour, Elias J.
    Wang, Tao
    Vandendries, Erik
    Laird, A. Douglas
    Nick, Sonja
    Stelljes, Matthias
    BLOOD, 2018, 132
  • [28] Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
    Chen, Joseph
    Haughey, May
    Vandendries, Erik
    DeAngelo, Daniel J.
    Kantarjian, Hagop M.
    Ruiz-Garcia, Ana
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (01): : 184 - 193
  • [29] HOSPITALIZATION FOR PATIENTS IN THE US AND EU TREATED WITH INOTUZUMAB OZOGAMICIN VS STANDARD OF CARE FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN A GLOBAL PHASE 3 TRIAL
    Su, Y.
    Van Oostrum, I.
    Vandendries, E.
    Welch, V.
    Loberiza, F. R.
    HAEMATOLOGICA, 2017, 102 : 344 - 344
  • [30] Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia
    Stock, Wendy
    Martinelli, Giovanni
    Stelljes, Matthias
    DeAngelo, Daniel J.
    Goekbuget, Nicola
    Advani, Anjali S.
    O'Brien, Susan
    Liedtke, Michaela
    Merchant, Akil A.
    Cassaday, Ryan D.
    Wang, Tao
    Zhang, Hui
    Vandendries, Erik
    Jabbour, Elias
    Marks, David, I
    Kantarjian, Hagop M.
    CANCER, 2021, 127 (06) : 905 - 913
12345